From Saucy Pics To Passwords: How To Share Sensitive Information

Raise your hand if youve shared a username and password with someone over IM? Ever share a document with your SSN or other extremely sensitive information without protecting it? How about if youve sent, erm scandalous pics to your significant other? Thanks to the internet, we share more than ever, and so quickly and easily, that we do it without a second thought. Thats great, but it may be time you learn a little about how to do that sharing in a more secure fashion.

Title image remixed from Mayer George Vladimirovich and mkabakov.

Here well walk through the easiest and most secure ways to share files, passwords and other data with people you trust. There are countless other methods out there, but these are our favourites. The method you use to share data should depend on what youre sending, how secure you want that material to be, and how willing you are to take proper security methods.

If youre just sending a username, password or other line of text (like a credit card number), protect your info with a few simple tricks:

Sometimes all it takes to increase your security is a little obscurity, and thats what this method is all about. You send the sensitive data over separate channels so that only the recipient is likely to have context for what it all means. Lets say you wanted to share a username and password with someone over the internet. Heres the basic idea:

1. In an email, send the username with an accompanying message something like Ive texted you the FTP password. 2. Text the password separately, with no context. 3. The recipient receives the password, saves it elsewhere and deletes the text message.

Even if your recipient doesnt delete the message (which you cant count on), a snoop would have no context for what it applies to. The basic idea could work in any direction, as long as youre separating the context from the information. Is it 100 per cent foolproof? Absolutely not. But its better than nothing, which is what many of us are doing now.

If you want to get even more creative, you could send someone the first half of the password via SMS, the second half via email, and let the recipient know over IM how its been broken up. That way, a thief would have to have access to both the email, IM account and the phone. You get the idea.

Password management service LastPass is still one of the most secure ways to create and store passwords. If your recipient is also using it (or if you can convince them of how great it is and get them signed up), sharing passwords and other small notes securely is extremely easy. Just pop into your LastPass vault, click the Share link next to the password or secure note you want to share, type in your recipients email address, and LastPass will take care of the rest securely. If youre sharing login credentials, you can choose to share the actual password (so your recipient can learn what it is) or just share access to the credentials in question, so your friend or colleague can log without actually learning your password. For more info on how to share passwords with LastPass, check out our how-to on the subject.

If you need to send full documents like paperwork for your job or a saucy photo youll need the help of an external service. Here are our favourite ways to securely send files.

Go here to see the original:

From Saucy Pics To Passwords: How To Share Sensitive Information

New Mobile Application Rates Smiles – Find Out How People Are Loving Their Smiles More Than Ever

A new mobile application allows a professional cosmetic dentist in San Francisco grade users smile and give feedback on ways a licensed cosmetic dentist can improve lives. This amazing new mobile application will allow anyone to anonymously upload peoples smile for grading.San Francisco, Ca (PRWEB) May 15, 2012 Dr Jorge Peter Rabanus is a leading cosmetic dentist in San Francisco and has just ...

Continue reading here:

New Mobile Application Rates Smiles - Find Out How People Are Loving Their Smiles More Than Ever

At Content Creators, journalists practice their craft and get paid

May 15, 2012

By Julia Scott Tim Collie stumbled upon a universal truth while building his news startup, Content Creators. Most people dont like their website. The design is bad, or they dont know how to upload videos. The content stagnates, and the site becomes a calling card appended with excuses.

Imagine then, that you get a cold call from Collie, 51.

Were story tellers, his pitch goes. Weve looked at your website. We believe we can help provide you with content and videos.

Talk about full service. Content Creators offers ghostwriting, editing, website design, photography, video, social media, and any other kind of content creation you can think of. Folks who design websites dont typically follow up by providing content and keeping the thing bug-free.

Content Creators does. In fact, it is rare that they are hired to create a website and not contribute the content.

Its one reason why the start up, barely three years old, makes enough to pay out of state college tuition for Collies two sons.

We are willing to work with people who have basic skills, he said. Not that he and his two partners, photographer and videographer Andrew Innerarity and business manager Jodie Knofsky, have left their day jobs. Collie edits the political news website Newsmax.com.

Content Creators is based in South Florida and covers three counties, Broward, Palm Beach, and Miami-Dade. Instead of having a main office, Collie and his partners work from home and on the road. Were kind of virtual, he said. We can move anywhere.

Eighty percent of the work is done by Collie and his two partners. The rest is contractors. Expenses are minimal. Gas money eats up a chunk of change. Indemnity insurance is another big ticket at a few hundred bucks a month.

Originally posted here:

At Content Creators, journalists practice their craft and get paid

US Army internal medicine Masters, Fellows honored by American College of Physicians

Public release date: 15-May-2012 [ | E-mail | Share ]

Contact: Zina Poletz zpoletz@webershandwick.com 612-719-2024 Weber Shandwick Worldwide

FORT KNOX, Ky., May 15, 2012 The U.S. Army Medical Department announced today the election of two of its own to Mastership in the American College of Physicians (MACP). Only 43 medical leaders from around the world who have achieved eminence through their contributions to the field of internal medicine in at least one area, such as practice, teaching, research or volunteerism, were awarded a Mastership in 2012. One of the Masters, Col. Gregory J. Argyros, M.D., MACP, who is board-certified in critical care medicine, pulmonology and internal medicine, is director of education, training and research for the Joint Task Force National Capital Region Medical, and professor of medicine at the Uniformed Services University of the Health Sciences. He previously served as chief of medicine and director of the internal medicine residency program at Walter Reed Army Medical Center, and as the ACP Army Chapter Governor from 2005-2009. In addition, Dr. Argyros has received numerous teaching awards over the years.

Recently retired as an Army colonel after a 27-year career, Alan J. Magill, M.D., MACP, was also honored as a Master by the College. Dr. Magill is currently a program manager at the Defense Advanced Research Projects Agency, where he develops effective interventions in the event of an influenza epidemic. He previously served as director of the Division of Experimental Therapeutics at the Walter Reed Army Institute of Research, and is an attending physician with the Infectious Disease Service at Walter Reed National Military Medical Center. He also teaches at the Uniformed Services University of the Health Sciences. Dr. Magill has held leadership positions in infectious disease at the National Institute of Health, International Society of Travel Medicine, American Society of Tropical Medicine and Hygiene, and other organizations.

"That two Army physicians were inducted as Masters by the American College of Physicians speaks to the high quality of physicians who choose to make the Army their career and the extraordinary opportunities Army medicine offers them," said Col. Jeanne Tofferi, M.D., MPH, FACP, internal medicine consultant to the Army Surgeon General. "Both of them have made tremendous contributions to our nation through teaching, medical practice and research."

On April 19, during the ACP annual meeting in New Orleans, six Army internal medicine physicians and subspecialists joined their Army ACP Chapter Governor, Col. Lisa Zacher, M.D., FACP, for a convocation ceremony during which they were inducted as Fellows of the American College of Physicians (FACP). These physicians included: Lt. Col. Michael G. Rossman, M.D. (Rheumatology), Daniel W. Franks, D.O. (Internal Medicine), Maj. Kimberly C. Salazar (Allergy/Immunology), Maj. Paige E. Waterman, M.D. (Infectious Disease), Anne B. Rossignol, M.D. (Hospice Care & Palliative Medicine) and Mark Garfinkle, M.D. (Internal Medicine).

Criteria for Fellowship include board certification by the American Board of Internal Medicine, recognition by other internists for excellence and skill in medical practice, teaching or research, and commitment to continued education and advanced training. Fellows of ACP are recommended by their peers based on character, ethics and excellence in medical practice, and undergo the review by ACP's Credentials Subcommittee.

"The Army makes board certification and continuing medical education a top priority," said Col. Zacher, who is also the pulmonary consultant to the Army surgeon general and chief, Department of Medicine, Brooke Army Medical Center. "The fact that so many Army physicians have become Fellows of the ACP speaks to their professional excellence in internal medicine and dedication to the highest quality of patient care."

The following Army internists and subspecialists were elected as Fellows in 2012 (listed by Army medical center or affiliation):

Walter Reed National Military Medical Center (Washington, D.C.) Col. Ronald D. DeGuzman, M.D. (Allergy/Immunology); Maj. Fouad J. Moawad, M.D. (Gastroenterology); Maj. James E. Moon, M.D. (Internal Medicine); Maj. Kristopher M. Paolino, M.D. (Infectious Disease); Maj. Sheri K. Dennison, M.D. (Hematology/Oncology); Maj. Aaron B. Holley, M.D. (Pulmonology/Critical Care Medicine); Maj. Jeffrey S. Kunz, M.D. (Cardiology); Maj. Kevin M. Woods, M.D. (Cardiology); Maj. Ganesh Veerappan, M.D. (Gastroenterology); Lt. Col. Paige E. Waterman, M.D. (Infectious Disease ); Maj. Jason A. Regules, M.D. (Infectious Disease)

The rest is here:

US Army internal medicine Masters, Fellows honored by American College of Physicians

BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing Through Mayo Medical Laboratories

WALTHAM, Mass., May 14, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD - News), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Mayo Medical Laboratory (Mayo) now offers galectin-3 testing services to its laboratory customers and physicians. Mayo will offer the BGM Galectin-3TM test, which was cleared by the U.S. Food and Drug Administration in November 2010, as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Galectin-3 testing provides physicians with clinical information on fibrosis formation and cardiac remodeling, which are important biological processes in the development and progression of heart failure. BG Medicine plans to continue to expand commercial availability of its BGM Galectin-3 test through major U.S. laboratories.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD - News) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3TM test for use in patients with heart failure, is available in the United States and Europe. BG Medicine has also developed CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this news release address our beliefs regarding the clinical utility of galectin-3 testing and our plans to expand commercial availability of galectin-3 testing services. Forward-looking statements are based on management's current expectations and involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Read more:

BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing Through Mayo Medical Laboratories

The medicine cabinet quiz

Most medicine cabinets contain a jumble of over-the-counter health products, but knowing what to use, when, can be confusing. Just because a medication is sold without a prescription doesn't mean it is harmless, and some old standbys can do more harm than good. Based on consultations with experts and reference materials, here is a deceptively easy quiz from The Wall Street Journal to test your home-remedy literacy.

1. You have a headache. Should you take: A) Advil (ibuprofen) B) Tylenol (acetaminophen) C) Aspirin

Answer: A, B or C

All of them will relieve a simple headache, but through different means and with different side effects.

Advil and Motrin (ibuprofen), Aleve (naproxen sodium) and aspirin all reduce pain by fighting inflammation, which also makes them particularly useful for combating arthritis, tooth pain, menstrual cramps and muscle sprains. But they can cause stomach bleeding, so people with peptic ulcers, liver, kidney or heart disease should talk to their doctors before taking them.

Aspirin has the added benefit of preventing blood clots, which is why taking one daily can lower the risk of cardiovascular disease. But aspirin shouldn't be used by people who have low blood pressure or open wounds, or by children who have the flu or chickenpox due to the risk of Reye's syndrome, a rare neurological disorder.

Tylenol (acetaminophen) works by calming pain signals in the brain. But it can cause liver damage if you regularly have three or more alcoholic drinks a day or take a higher dosage than recommended.

All in all, ibuprofen is arguably the strongest, but aspirin works faster, naproxen lasts longer and acetaminophen is safer if you have stomach problems (and aren't a heavy drinker). A few brands contain both acetaminophen and aspirin, but don't mix them on your own and don't take any of them for more than five days straight, since they can cause "rebound" headaches, in which the body feels withdrawal when they wear off.

2. To clean a cut or scrape, it is best to use: A) Hydrogen peroxide B) Isopropyl (rubbing) alcohol C) Neither D) Both

Answer: C

Excerpt from:

The medicine cabinet quiz

Welcome Molecules to Medicine the newest blog at #SciAmBlogs

I am very excited to announce the latest addition to the #SciAmBlogs network Molecules to Medicine, by Dr. Judy Stone.

Judy Stone, MD is an infectious disease specialist, experienced in conducting clinical research. She is the author of Conducting Clinical Research, the essential guide to the topic. As she says, she survived 25 years in solo practice in rural Cumberland, Maryland, and is now broadening her horizons. She particularly loves writing about ethical issues, and tilting at windmills in her advocacy for social justice. As part of her overall desire to save the world when she grows up, she has become especially interested in neglected tropical diseases. When not slaving over hot patients, she can be found playing with photography, friends dogs, or in her garden.

You can check out many years worth of archives on her old blog Politics, Science, and Other Assorted Musings, or follow her on Twitter @drjudystone.

If you are a regular reader of the Scientific American Guest Blog, you have probably read several of Dr.Stones previous posts:

Molecules to Medicine: Clinical Trials for Beginners Molecules to Medicine: From Test-Tube to Medicine Chest Lillys Shocker, or the Post-Marketing Blues Molecules to Medicine: Pharma Trumps HIPAA? Molecules to Medicine: Should pepper spray be put on (clinical) trial? Molecules to Medicine: FDA at a Crossroadsa Tough Place to Be Molecules to Medicine: Plan B: The Tradition of Politics at the FDA Molecules to Medicine: Conscience Clauses versus Refusal: An Historical Perspective Molecules to Medicine: When Religion Collides with Medical Care: Who Decides What Is Right for You? A Taste of #TEDMED 2012: Appetizers A Taste of #TEDMED 2012: Main Course Molecules to Medicine: Have You Thanked a Clinical Researcher Today? Molecules to Medicine: Public Health or Impaired Penises?

Now go and say Hi to Judy in the comments on her first post, then subscribe to or bookmark her blog so you dont miss the future posts.

Continue reading here:

Welcome Molecules to Medicine the newest blog at #SciAmBlogs

BG Medicine Announces Publication of First Study on Use of Galectin-3 in Selection of Drug Therapy in Heart Failure

WALTHAM, Mass., May 14, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD - News), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that results from a sub-study of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial were published online in the current issue of the European Heart Journal.1 Study results demonstrated that patients with blood levels of galectin-3 below 19.0 ng/mL at the start of the trial derived significant clinical benefit from rosuvastatin (statin) treatment. By contrast, no clinical benefit from rosuvastatin treatment was observed among participants with higher levels of galectin-3.

The galectin-3 CORONA study was designed to assess whether baseline galectin-3 levels could distinguish a group of patients with heart failure who would derive a clinical benefit from rosuvastatin treatment. Rosuvastatin, known under the brand name CRESTOR(R), is a statin medication indicated for the treatment of high cholesterol and related lipid disorders to reduce the risk of heart attack and stroke. The sub-study involved 1,462 trial participants (approximately one-third of all CORONA trial subjects). Results demonstrated that patients with plasma levels of galectin-3 less than 19.0 ng/mL derived a 35% reduction in primary adverse cardiovascular events while on rosuvastatin treatment compared to placebo, while no comparable benefit was observed in subjects with plasma levels of galectin-3 above 19.0 ng/mL (p=0.036). The primary endpoint was a composite of cardiovascular mortality, non fatal myocardial infarction and non fatal stroke, which were analyzed as time to first event.

"Heart failure is a leading cause of death, and galectin-3 is increasingly recognized as a factor in promoting cardiac fibrosis and poor clinical outcomes in many heart failure patients," said Dr. Lars Gullestad, MD, PhD, Professor of Cardiology in the Department of Cardiology at Rikshospitalet University Hospital, Oslo, Norway, who led the study.

"This important study reaffirms a key premise of our galectin-3 research, namely that galectin-3 identifies heart failure patients with a distinct form of the disease," said Pieter Muntendam, MD, Executive Vice President and Chief Medical Officer of BG Medicine. "We expected that the benefit of certain drugs may be limited to patient groups defined by their level of galectin-3 and this is an excellent example of such differential benefit."

The original CORONA study was designed to evaluate the utility of rosuvastatin treatment for patients with advanced heart failure. Results from that trial, reported in the New England Journal of Medicine in 2007, demonstrated no rosuvastatin benefit on the primary coronary endpoint or on cardiovascular death.2

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD - News) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3TM test for use in patients with heart failure, is available in the United States and Europe. BG Medicine has also developed CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this news release address our expectations concerning the role that galectin-3 plays in heart failure and how therapeutic treatment decisions will be influenced by classification of heart failure patients according to galectin-3 levels, our expectations regarding the importance of the galectin-3 data published in the European Heart Journal, and the impact of the galectin-3 data on the sales and marketing of our galectin-3 diagnostic tests. Forward-looking statements are based on management's current expectations and involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Original post:

BG Medicine Announces Publication of First Study on Use of Galectin-3 in Selection of Drug Therapy in Heart Failure

Sports Medicine Skills Come Into Play at Pasadena Marathon

PASADENA, Calif.--(BUSINESS WIRE)--

Just as athletes are training for the upcoming May 20, 2012 Kaiser Permanente Pasadena Marathon so, too, are the physicians and health professionals who are responsible for providing medical care for the events walkers, runners and cyclists.

Kaiser Permanente takes these events very seriously, says Thad Woodward, MD, a Family Practice and Sports Medicine physician at the Kaiser Permanente Woodland Hills Medical Center, who has supervised medical response for the Pasadena Marathon for the past four years. We try to bring the same level of care for our athletes in the field as we do for our patients in the emergency room.

About 40 to 60 Kaiser Permanente physicians, health professionals and other community volunteers are expected onsite to meet the basic medical needs of participants for the entire course. Leading their efforts will be James Hwang, MD, and Joel Ramirez, MD, sports medicine fellows at the Kaiser Permanente Los Angeles Medical Center.

To ensure their health care team is ready for nearly anything, the pair will bring Kaiser Permanente Southern Californias 25-bed disaster medical tent. Equipped with solid floors and air conditioning, the tent can double as a command post. Future plans call for installing wireless Internet and satellite phones.

Its like a MASH tent with cots, IVs, and medical supplies, says Dr. Hwang. Its very well stocked. You can do basic triage and stabilize patients before transferring them to the nearest hospital.

Use of the tent, which can expand to 1,700 square feet, ranges from medical center emergencies to area sporting events. Once the tent is fully equipped and operational, it can potentially be used for regional and out-of-state emergencies. During the Kaiser Permanente Pasadena Marathon, the disaster medical tent will be set up near the finish line while smaller tents will be erected along the event route.

Sports medicine physicians say they are especially well-suited to responding to medical emergencies at sporting events such as the Kaiser Permanente Pasadena Marathon. We cover the whole gamut of health issues, from primary care to musculature skeletal issues, says Dr. Hwang. Its nice that the Pasadena Marathon showcases our skills set; it lets the community know what sports medicine is really about.

Dr. Ramirez, who routinely gives community talks on the importance of education, says the Pasadena Marathon is an excellent opportunity for high school and college students who are considering medicine as a career.

They can see injuries and they can help us with cleaning abrasions or lacerations, says Dr. Ramirez. Its a great opportunity to learn whether medicine is the right career for you.

View original post here:

Sports Medicine Skills Come Into Play at Pasadena Marathon

BG Medicine, Inc. Obtains CE Mark and Files 510(k) for Expanded BGM Galectin-3(TM) Indication

WALTHAM, Mass., May 15, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD - News), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it has filed a 510(k) Premarket Notification with the U.S. Food and Drug Administration (FDA) for regulatory clearance of an expanded indication for its BGM Galectin-3 test. The blood test was cleared by the FDA in November 2010 and is currently indicated for use in patients with chronic heart failure who are at increased risk for hospitalizations or death based on elevated levels of galectin-3. Subject to FDA clearance, the new application would expand the indicated use to the general adult population to identify those with an elevated level of galectin-3, which is associated with an increased risk for new-onset heart failure.

The Company also announced that it has obtained CE Mark in the European Union (EU) for the expanded indication for the BGM Galectin-3 test, and is working with its partners to begin commercialization for the expanded indication in the EU.

The validation study that supports the expanded indication was conducted by the Framingham Heart Study. Led by the National Heart Lung and Blood Institute (NHLBI), the Framingham Heart Study (FHS) is a leading, prospective, observational, family multi-generational study designed to track the development of cardiovascular disease and elucidate its common contributing factors. The study was initiated in 1948 and is a widely-used, generally-accepted, authoritative source that addresses risk factors associated with cardiovascular risks and disease. The study reported that approximately 15% of the general adult population was found to have elevated levels of galectin-3. Individuals with elevated levels of galectin-3 had a clinically important and statistically significant 47% increase in risk for the development of new-onset heart failure.

"Our initial indication pertains to progression in established heart failure," said Pieter Muntendam, MD, Executive Vice President and Chief Medical Officer at BG Medicine. "This new indication addresses the importance of galectin-3 in heart failure development. The two indications combined span the galectin-3 mediated disease process from subclinical disease in those who seem otherwise healthy to those who suffer from advanced heart failure disease with high mortality."

"Heart failure today affects approximately 20 million people in the United States and Europe," said Eric Bouvier, President and Chief Executive Officer of BG Medicine. "Subject to clearance by the FDA, the expanded indication would address a potential market of approximately 200 million people in the United States and Europe. We believe that identifying at-risk individuals before the development of heart failure would allow physicians to offer enhanced risk reduction strategies to their patients, potentially resulting in improved patient outcomes."

About Galectin-3 and Heart Failure

Galectin-3 is a unique carbohydrate-binding lectin, or protein, that binds to carbohydrates called beta-galactosides. It has been implicated in a variety of biological processes important in heart failure, and is believed to be a primary mediator of progressive cardiac fibrosis (abnormal thickening and stiffening of the heart muscle) and adverse remodeling (changes in the structure of the heart). Higher levels of galectin-3 are associated with a more aggressive form of heart failure and 30% or more of mild to moderate heart failure patients have elevated levels of galectin-3. Heart failure affects an estimated 5.8 million Americans, with approximately 670,000 new cases occurring each year. The direct and indirect cost of heart failure in the United States for 2010 is estimated to be $39.2 billion.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD - News) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3TM test for use in patients with heart failure, is available in the United States and Europe. BG Medicine has also developed CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Read the rest here:

BG Medicine, Inc. Obtains CE Mark and Files 510(k) for Expanded BGM Galectin-3(TM) Indication

Heel Supports New International Research Prize in Integrative Medicine

BADEN-BADEN, Germany--(BUSINESS WIRE)--

The European Society for Integrative Medicine (ESIM), with support from Heel, announces a new international research prize in integrative medicine: the Excellence in Integrative Medicine Research Award. Applicants are asked to submit papers by May 30, 2012.

This international research prize recognizes innovative and outstanding scientific papers in the field of integrative medicine, thus fostering collaboration between conventional and complementary medicine, emphasizes Dr. Ghassan Andraos, Head of Global Medicine at Biologische Heilmittel Heel GmbH.

The ESIM research prize is awarded in two categories: one for clinical investigations, the other for basic research. Each of the two winners will be awarded the sum of 10, 000 euros. Submissions must be based on a scientific manuscript that has either already been published in a peer-reviewed journal in 2011 or 2012 or has been accepted for publication. The jury, which is made up of a selection of international experts in integrative medicine, will rate the papers according to three criteria: innovation, level of relevance and scientific excellence.

The winners of the Excellence in Integrative Medicine Research Awards will be announced at the 5th annual European Conference on Integrative Medicine (ECIM) to be held in Florence, Italy from September 21 to 22. For more information, visit: http://www.ecim-congress.org.

The mission of the European Society for Integrative Medicine is to promote science, research, education and further training, support for medical care and providing advice on policy in the realm of integrative medicine. For these purposes, the Society organizes scientific events and encourages dialog with health-care authorities and institutions.

Heel is a pharmaceutical company that develops, manufactures and distributes medicines based on natural substances. As the global leader in homeopathic combination preparations, the company is also a pioneer in the field of scientific research in natural healthcare. In cooperation with academic institutions, Heel actively fosters the concept of integrative medicine and is building the bridge between homeopathy and conventional medicine to improve patient care and health.

Biologische Heilmittel Heel GmbH, with corporate headquarters located in Baden-Baden/Germany and a staff of 1,300, achieved an annual turnover of 196 million euros in 2011 70 percent of it outside of Germany. Heel medicinesare available through subsidiaries and distribution partners in over 50 countries around the world. http://www.heel.com

See original here:

Heel Supports New International Research Prize in Integrative Medicine

BG Medicine Announces Fiscal 2012 First Quarter Results

WALTHAM, Mass., May 15, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD - News) today announced its consolidated results of operations for the first quarter of fiscal year 2012 and provided a business update. The Company will host a conference call and webcast today, May 15, 2012, beginning at 8:00 a.m. Eastern Time (details follow below).

At March 31, 2012, the Company had consolidated cash and cash equivalents totaling approximately $28.5 million.

For the quarter ended March 31, 2012, the Company reported a consolidated net loss of $7.7 million compared to a consolidated net loss of $3.1 million for the quarter ended March 31, 2011.

Business Update

"Our accomplishments over the past several months have created strong momentum toward achieving our goals for the BGM Galectin-3 TM test, CardioSCORE, and the Company as a whole," said Eric Bouvier, president and CEO of BG Medicine. "First, in May 2012, we filed a 510(k) to extend the approved labeling indication for the BGM Galectin-3 test to include individuals in the general adult population who are at risk for developing heart failure based on elevated levels of galectin-3. Second, we obtained CE Mark in the European Union for the expanded indication for the BGM Galectin-3 test and we are working with our partners to begin commercialization. Third, results from a sub-study of the CORONA trial, demonstrating the ability to use galectin-3 levels to identify heart failure patients who might benefit from therapy with a common statin drug, Crestor(R) (rosuvastatin), were recently published online in the European Heart Journal. Finally, we recently announced that Mayo Medical Laboratories is now making galectin-3 testing available to their networks, further demonstration of the increasing interest and demand for the BGM Galectin-3 test.

"In February, we entered into a $15.0 million secured loan facility with General Electric and Comerica and drew down $10.0 million," continued Mr. Bouvier. "This financing provides us with additional capital to fund our commercialization activities for both Galectin-3 and CardioSCORE.

"In addition to these recent accomplishments, several upcoming milestones will impact the success of BG Medicine in 2012 and beyond," concluded Mr. Bouvier. "We are focused on the achievement of these milestones and on making both Galectin-3 and CardioSCORE medical and commercial successes."

Upcoming milestones include:

Financial Results

Product revenue for the quarter ended March 31, 2012 increased to $416,000 from $12,000 in the quarter ended March 31, 2011, reflecting increasing demand for the BGM Galectin-3 test. On a sequential quarterly basis, product revenue increased 36% to $416,000 from $307,000 in the quarter ended December 31, 2011. Service revenue decreased to $64,000 in the quarter ended March 31, 2012 from $843,000 in the corresponding period in 2011. In the quarter ended March 31, 2011, service revenue consisted primarily of $700,000 related to an agreement under the HRP initiative. On a sequential quarterly basis, service revenue decreased to $64,000 from $72,000 in the quarter ended December 31, 2011.

Read more from the original source:

BG Medicine Announces Fiscal 2012 First Quarter Results

Global Alternative Medicine Industry

NEW YORK, May 14, 2012 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Global Alternative Medicine Industryhttp://www.reportlinker.com/p0151179/Global-Alternative-Medicine-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Alternati

The global outlook series on the Alternative Medicine Industry provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. Illustrated with 31 fact-rich market data tables, the report offers a rudimentary overview of the industry, and highlights latest trends and demand drivers. Regional markets briefly abstracted and covered include United States, Canada, Japan, Europe, UK, Denmark, India, Australia, and Taiwan among others. The report offers a compilation of recent mergers, acquisitions, and strategic corporate developments. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 433 companies worldwide.

1. INDUSTRY OVERVIEW 1Outlook 1Current Scenario 1Key Global Statistics 3Table 1: World Recent Past, Current & Future Analysis forTraditional Medicine by Geographic Region - North America,Europe, Asia-Pacific (including Japan), and Rest of WorldMarkets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2010 through 2015 3

Table 2: World 5-Year Perspective for Traditional Medicine

Market by Geographic Region: Percentage Breakdown of Value

Sales for North America, Europe, Asia-Pacific (including

Japan) and Latin American Markets for Years 2011 & 2015 4

Table 3: Percentage of Population in the Developed CountriesUsing Complementary and Alternative Medicine (CAM) (2011) 4Factors Driving the Market Growth 4Market Challenges 5Alternative Medicine - Down the Time Lane 5Table 4: World Alternative Medicine Market (2011): PercentageShare Breakdown by Type of Modality - Herbal Medicine,Traditional Chinese Medicine, Homeopathic Medicine, andAyurvedic Medicine 6Market Dynamics 6Rising Health Care Costs Drive Market Growth 6Table 5: Global Healthcare Market (2010): Breakdown of PerCapita (US$) Health Expenditure by Select Countries 7

Table 6: Global Healthcare Market (2010): Breakdown of

See original here:

Global Alternative Medicine Industry

Emory medical school gets $5 million gift

ATLANTA (AP) - The Emory University School of Medicine has received a commitment for a $5 million gift for its pediatrics department.

The money from the Marcus Foundation, Inc., will be used to create the Marcus Society in Pediatrics. The society will be the "intellectual home" for 15 Marcus Professors in Pediatrics_six existing Marcus Professors and nine who are newly funded. The society will also host an annual visiting scholar.

The nine new Marcus Professors will specialize in the following areas: rheumatology, general pediatrics/adolescent medicine, emergency medicine/faculty development, cystic fibrosis, neurology, immunology, cardiology, general academic pediatrics/hospital medicine and hospital epidemiology/infection control. The six existing Marcus Professors specialize in pulmonology, infectious diseases, nephrology, gastroenterology, endocrinology and neonatology.

The foundation and the department of pediatrics have a longstanding philanthropic relationship.

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Here is the original post:

Emory medical school gets $5 million gift

House okays for-profit medical school

PROVIDENCE, R.I. -- The House voted 65 to 6 Tuesday to permit a for-profit osteopathic medical school to open in Rhode Island, provided it meets applicable academic standards.

State Rep. Joseph M. McNamara, D-Warwick, presented the proposal as a boost to economic development that will create 300 jobs and bring construction of a 250,000-square-foot facility.

He also said the new Rhode Island School of Osteopathic Medicine would help address a projected shortage of primary care physicians in the next decade.

But State Rep. Edith H. Ajello, D-Providence, said the shortage of doctors stems from low reimbursement rates. She raised concerns that the school might not require students to have bachelors degrees and that it would strain available clinical placements for upper-level medical students.

Read more:

House okays for-profit medical school

Medical Students Should Study Patients' Cultural Diversity

As the United States grows more culturally diverse and we hear more languages spoken around us, clinical medical education has had to evolve as well. And with national population growth, particularly in big cities like New York and Los Angeles, which are popular with medical students, those students must not only know their jobs, but also need to know their hospitals.

Read the original here:

Medical Students Should Study Patients' Cultural Diversity

Seventy Medical Students Take a Year-Long Plunge into Lab Work

Medical school can be a grueling four-year journey consisting of never-ending memorization, clinical rotations and sleepless nights. So why do some students extend their medical school status by plunging into a research lab for an extra year of studies?

Its all about the why, explains Dylan Wolman, a medical student at Tufts University School of Medicine. A year of research provides an avenue to practice what should be an essential skill in any scientific field: questioning 'why. It is a thought exercise that will serve you there by teaching you to question why an unexplained symptom in a particular disease constellation occurs, and perhaps even help you develop the spark necessary to pursue that question to its answer, Wolman says.

Wolman and another medical student awardee will immerse themselves in a year of intense lab research at the Howard Hughes Medical Institutes Janelia Farm Research Campus as part of the HHMI Medical Research Fellows Program, a $2.5 million annual initiative to increase the training of future physician-scientists. In all, 70 students from 27 medical schools across the country will participate in the year-long Medical Research Fellows Program. More than 1,400 students have participated in the Medical Research Fellows program since its inception in 1989.

A year spent focused on research has been transformative for many fellows, and shaped their interest and determination to become physician-scientists. Sean B. Carroll

Wolman, who is halfway through his medical studies at Tufts, is taking a year off from medical school to conduct cutting-edge research on brain wiring at Janelia Farm in Ashburn, Virginia. At Janelia Farm, Wolman will use light and electron microscopy techniques to study the neural connectivity between the mouse motor and barrel cortex. He will work under the mentorship of Janelia Farm fellow Davi Bock and group leader Karel Svoboda.

A year spent focused on research has been transformative for many fellows, and shaped their interest and determination to become physician-scientists, says Sean B. Carroll, HHMIs vice president for science education.

One of the medical research fellows will spend a part of his year researching tuberculosis in South Africa. Eric Kalivoda, a student from the University of Vermont College of Medicine, will work at the KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), in Durban, South Africa, for several months under the mentorship of HHMI investigator William Jacobs. This is the first time that one of the medical fellows will be spending a portion of the fellowship year at K-RITH.

K-RITH is a groundbreaking collaboration between HHMI and the University of KwaZulu-Natal in South Africa. K-RITHs mission is to conduct outstanding basic science research on tuberculosis (TB) and HIV, translate the scientific findings into new tools to control TB and HIV, and expand the educational opportunities in the region. Kalivoda will travel to Durban mid-way through his fellowship, and then return to the United States to spend the rest of the year in Jacobs lab at the Albert Einstein College of Medicine in New York.

K-RITH offers the unique perspective to study and address HIV/XDR-TB at its epicenter, and I look forward to working with my mentor and the K-RITH team of scientists to develop improved diagnostics for rapid TB drug-susceptibility testing, said Kalivoda.

David McMullen, a fellow from the Robert Wood Johnson Medical School in New Jersey, will spend the year doing research on brain-computer interfaces in a non-HHMI lab at Johns Hopkins University. McMullen will work with Hopkins scientists who are developing brain-computer interface technology as a potential treatment that would help patients with neuromuscular damage regain motor function.

Read more:

Seventy Medical Students Take a Year-Long Plunge into Lab Work